Citations

Mayo Clinic

Clear

399 citation(s) found for "Muñoz, Rodrigo".

Internalization ofClostridium perfringensα-toxin leads to ERK activation and is involved on its cytotoxic effect
Monturiol‐Gross, Laura , Flores-Dı́az, Marietta, Campos-Rodríguez, Diana, Rodríguez-Vega, Mariela, Marks, David L. , Alape‐Girón, Alberto , Mora, Rodrígo

Cellular Microbiology | November 19, 2013 | Volume: 16 | Issue: 4 | Pages: 535-547

10.1111/cmi.12237 | PMID 24245664 Get It

The Dynamic Architectural and Epigenetic Nuclear Landscape: Developing the Genomic Almanac of Biology and Disease
Zaidi, Sayyed K. , Wu, Hai , Grandy, Rodrigo A. , Montecino, Martı́n , Wijnen, André J. van , Lian, Jane B. , Stein, Gary S., Stein, Janet L. , Tai, Phillip W.L. , van Wijnen, Andre J

Journal of Cellular Physiology | November 15, 2013 | Volume: 229 | Issue: 6 | Pages: 711-727

10.1002/jcp.24508 | PMID 24242872 Get It

Desmoid tumors of the head and neck: A therapeutic challenge
Bree, Eelco de , Zoras, Odysseas , Hunt, Jennifer L., Takes, Robert P. , Hinni, Michael L., Rodrigo, Juan P. , Shaha, Ashok R. , Rinaldo, Alessandra , Ferlito, Alfio , Suarez, Carlos M. , Mendenhall, William M , Bree, Remco de , Rodrigo, Juan P

Head & Neck | October 12, 2013 | Volume: 36 | Issue: 10 | Pages: 1517-1526

10.1002/hed.23496 | PMID 24421052 Get It

AbstractDesmoid tumor, or aggressive fibromatosis, is a rare, histologically benign, fibroblastic lesion that infrequently presents in the head and neck. Desmoid tumors often grow locally, invasively, and may, in rare instances, be fatal secondary to invasion into critical structures, such as airway or major vessels. The most common treatment is surgery, but desmoid tumors are characteristically associated with a high local recurrence rate after resection. Although the margin status seems to be of importance, operations that avoid function loss and esthetic disfigurement should be the primary goal. The efficacy of postoperative radiotherapy is controversial. Its potential benefit should be carefully balanced against possible radiation‐induced adverse effects. Alternative treatment modalities, such as primary radiotherapy and medical treatment or a wait‐and‐see policy, may be preferable to mutilating surgery. Considering all the aforementioned, it seems obvious that desmoid tumors of the head and neck present a therapeutic challenge and require an individualized approach. © 2014 Wiley Periodicals, Inc.Head Neck, 36: 1517–1526, 2014
Predictors of Disseminated Intravascular Coagulation in Patients with Septic Shock
Kelm, Diana J. , Valerio-Rojas, Juan Carlos , Cabello-Garza, Javier, Cartin‐Ceba, Rodrigo , Gajic, Ognjen

ISRN Critical Care | October 2, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-6

10.5402/2013/219048 Get It

Purpose. The goal of this study was to identify potential clinical predictors for the development of disseminated intravascular coagulation (DIC) in patients with septic shock. Material and Methods. We performed a retrospective analysis of a cohort of adult (>18 years of age) patients with septic shock admitted to a medical ICU in a tertiary care hospital from July 2005 until September 2007. A multivariate logistic regression model was used to determine the association of risk factors with overt DIC. Results. In this study, a total of 390 patients with septic shock were analyzed, of whom 66 (17%) developed overt DIC. Hospital mortality was significantly greater in patients who developed overt DIC (68% versus 38%, P<0.001). A delay in the timing of antibiotics was associated with an increased risk of the development of overt DIC (P<0.001). Patients on antiplatelet therapy prior to hospital admission and who that received adequate early goal-directed therapy (EGDT) were associated with a decreased risk of overt DIC (P<0.001). Conclusions. In our cohort of patients with septic shock, there was a risk reduction for overt DIC in patients on antiplatelet therapy and adequate EGDT, while there was an increased risk of DIC with antibiotic delay.
Primary Antiphospholipid Syndrome–Associated Diffuse Alveolar Hemorrhage
Cartin‐Ceba, Rodrigo , Peikert, Tobias, Ashrani, Aneel A. , Keogh, Karina A., Wylam, Mark E. , Ytterberg, Steven R. , Specks, Ulrich

Arthritis Care & Research | August 27, 2013 | Volume: 66 | Issue: 2 | Pages: 301-310

10.1002/acr.22109 | PMID 23983016 Get It

Objective Diffuse alveolar hemorrhage (DAH) is an uncommon complication of primary antiphospholipid syndrome (APS). We aimed to describe the clinical characteristics, treatment, and outcomes of primary APS–associated DAH in a single center. Methods We conducted a retrospective review of all adults with primary APS–associated DAH evaluated at Mayo Clinic over a 15‐year period. DAH was defined as bilateral pulmonary infiltrates and bronchoalveolar lavage (BAL) fluid documenting progressively bloody returns and/or the presence of >20% hemosiderin‐laden macrophages. Patients with other causes of DAH were excluded. Results Eighteen patients were identified (median age 43 years). Capillaritis was present in surgical lung biopsy samples of 3 patients. BAL differential cell counts revealed predominantly neutrophils. All patients were treated initially with glucocorticoids. Cyclophosphamide (CYC) was used in 8 patients; complete remission was achieved in 3 patients treated with CYC alone and in 1 patient receiving combination therapy with rituximab (RTX). RTX was used in 9 patients; 2 patients achieved remission with RTX alone, whereas 3 patients required combination therapy with CYC or mycophenolate mofetil (MMF). No patient achieved complete remission while receiving single therapy with MMF, azathioprine, or plasma exchange. Intravenous gamma globulin therapy was administered in 5 patients; no patient achieved control of the disease. Six patients died, all because of complications related to uncontrolled DAH or its therapy. Conclusion We present the largest case series of primary APS–associated DAH reported in the literature. DAH carries a very poor prognosis and therapeutic options are limited. Immunosuppression with either CYC or RTX is associated with the highest likelihood of remission induction and should be considered early.
Validation of Computerized Automatic Calculation of the Sequential Organ Failure Assessment Score
Harrison, Andrew M. , Yadav, Hemang , Pickering, Brian W. , Cartin‐Ceba, Rodrigo , Herasevich, Vitaly , Harrison, Andrew Marc , Herasevich, Vitaly

Critical Care Research and Practice | July 9, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-8

10.1155/2013/975672 | PMID 23936639 Get It

Purpose. To validate the use of a computer program for the automatic calculation of the sequential organ failure assessment (SOFA) score, as compared to the gold standard of manual chart review.Materials and Methods. Adult admissions (age > 18 years) to the medical ICU with a length of stay greater than 24 hours were studied in the setting of an academic tertiary referral center. A retrospective cross-sectional analysis was performed using a derivation cohort to compare automatic calculation of the SOFA score to the gold standard of manual chart review. After critical appraisal of sources of disagreement, another analysis was performed using an independent validation cohort. Then, a prospective observational analysis was performed using an implementation of this computer program in AWARE Dashboard, which is an existing real-time patient EMR system for use in the ICU.Results. Good agreement between the manual and automatic SOFA calculations was observed for both the derivation (N=94) and validation (N=268) cohorts: 0.02 ± 2.33 and 0.29 ± 1.75 points, respectively. These results were validated in AWARE (N=60).Conclusion. This EMR-based automatic tool accurately calculates SOFA scores and can facilitate ICU decisions without the need for manual data collection. This tool can also be employed in a real-time electronic environment.
Relationship between reflux and laryngeal cancer
Coca‐Pelaz, Andrés , Rodrigo, Juan P. , Takes, Robert P. , Silver, Carl E., Paccagnella, Daniela, Rinaldo, Alessandra , Hinni, Michael L., Ferlito, Alfio , Rodrigo, Juan P , Coca-Pelaz, Andrés

Head & Neck | June 22, 2013 | Volume: 35 | Issue: 12 | Pages: 1814-1818

10.1002/hed.23208 | PMID 23794281 Get It

Gastroesophageal reflux disease (GERD), or its variation known as laryngopharyngeal reflux (LPR), has been recognized as a potential cause of several laryngeal disorders. Patients with laryngeal cancer have lifestyle risk factors, especially tobacco and alcohol consumption, that play an etiological role in the development of their cancer but also places them at risk for reflux. The question then arises whether there is merely an association or a causal relationship between laryngeal cancer and reflux. However, despite a number of studies, a causal relationship with laryngeal cancer is uncertain. In this article, we address the current literature in a critical manner to evaluate the relationship between reflux and laryngeal cancer. From the review of the literature, we conclude that there is insufficient evidence to support a causal role of reflux in laryngeal cancer, mainly because of the confounding effect of tobacco and alcohol consumption and the inaccuracies in the diagnosis of reflux. © 2013 Wiley Periodicals, Inc. Head Neck 35: 1814–1818, 2013
Contemporary Ventilator Management in Patients With and at Risk of ALI/ARDS
Chang, Steven Y., Dabbagh, Ousama, Gajic, O, Patrawalla, Amee , Elie, Marie‐Carmelle , Talmor, Daniel , Malhotra, Atul , Adesanya, Adebola, Anderson, Harry L, Blum, James M. , Park, Pauline K. , Gong, Michelle N. , (USCIITG-LIPS), on behalf of the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, (USCIITG-LIPS), the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, Talmor, Daniel S, Bender, S Patrick, Garcia, Mauricio, Hou, Peter C, Barry, Jonathan M, Shempp, Iam, Malhotra, Atul, Frendl, Gyorgy, Ahmed, Adil, Gajic, Ognjen, Malinchoc, Michael, Kor, Daryl J, Afessa, Bekele, Cartin-Ceba, Rodrigo, Gong, Michelle Ng, Gentile, Nina T, Stevenson, Karen, Freeman, Brent, Srinivasan, Sujatha, Sevransky, Jonathan, Chang, Steven Y, Patrawalla, Amee, Elie, Carmelle, Hamdani, Irram, Seiden, Jason, Douglas, Ivor, Mikkelsen, Mark, Christie, Jason D, Gaieski, David F, Lanken, Paul, Meyer, Nuala, Sha, Chirag, Park, Pauline K, Harris, Julie, Napolitano, Lena, Raghavendran, Krishnan, Hyzy, Robert C, Blum, James, Watkins, Timothy R, Deem, Steven, Treggiari, Miriam, Adesanya, Adebola, Sadikot, Ruxana, Hoth, J Jason, Yoza, Barbara, Festic, Emir, Kaufman, David, Bajwa, Ednan, Malhotra, Atul, Thompson, B Taylor, Christiani, David C, Cengiz, Melike, Yilmaz, Murat, Anderson, Harry, Tchorz, Kathryn, McCarthy, Mary C, Uddin, David, Iscimen, Remzi, Dabbagh, Ousama, Kallenbach, Nena, Esper, Anette, Martin, Greg, Bajwa, Ednan K. , Douglas, Ivor S. , Frendl, György , Chang, Steven Y. , Anderson, Harry L, (USCIITG-LIPS), on behalf of the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, (USCIITG-LIPS), the United States Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators, Talmor, Daniel S, Bender, S Patrick, Garcia, Mauricio, Hou, Peter C, Barry, Jonathan M, Shempp, Iam, Malhotra, Atul, Frendl, Gyorgy, Ahmed, Adil, Gajic, Ognjen, Malinchoc, Michael, Kor, Daryl J, Afessa, Bekele, Cartin-Ceba, Rodrigo, Gong, Michelle Ng, Gentile, Nina T, Stevenson, Karen, Freeman, Brent, Srinivasan, Sujatha, Sevransky, Jonathan, Chang, Steven Y, Patrawalla, Amee, Elie, Carmelle, Hamdani, Irram, Seiden, Jason, Douglas, Ivor, Mikkelsen, Mark, Christie, Jason D, Gaieski, David F, Lanken, Paul, Meyer, Nuala, Sha, Chirag, Park, Pauline K, Harris, Julie, Napolitano, Lena, Raghavendran, Krishnan, Hyzy, Robert C, Blum, James, Watkins, Timothy R, Deem, Steven, Treggiari, Miriam, Adesanya, Adebola, Sadikot, Ruxana, Hoth, J Jason, Yoza, Barbara, Festic, Emir, Kaufman, David, Bajwa, Ednan, Malhotra, Atul, Thompson, B Taylor, Christiani, David C, Cengiz, Melike, Yilmaz, Murat, Anderson, Harry, Tchorz, Kathryn, McCarthy, Mary C, Uddin, David, Iscimen, Remzi, Dabbagh, Ousama, Kallenbach, Nena, Esper, Anette, Martin, Greg

Respiratory Care | April 6, 2013 | Volume: 58 | Issue: 4 | Pages: 578-588

10.4187/respcare.01755 | PMID 22906363 Get It

Outcomes of Severe Sepsis and Septic Shock Patients on Chronic Antiplatelet Treatment: A Historical Cohort Study
Valerio-Rojas, Juan Carlos , Jaffer, Insara J., Kor, Daryl J. , Cartin‐Ceba, Rodrigo , Gajic, Ognjen

Critical Care Research and Practice | February 20, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-9

10.1155/2013/782573 | PMID 23509620 Get It

Background. Sepsis is characterized by dysfunctional activation of platelets, and antiplatelet therapy could improve the outcomes of septic patients.Methods. We performed a retrospective cohort study of severe sepsis or septic shock adult patients. Outcomes of patients on antiplatelet therapy were compared to those that were not taking antiplatelet therapy by univariate analysis followed by a propensity score analysis based on the probability of receiving antiplatelet therapy.Results. Of 651 patients included in the study 272 (42.8%) were on antiplatelet therapy before the development of severe sepsis or septic shock. After adjusting for important confounding variables antiplatelet therapy was not associated with a decreased risk of hospital mortality (odds ratio 0.73, 95% confidence interval 0.46–1.16). Antiplatelet therapy was associated with a decreased incidence of acute respiratory distress syndrome/acute lung injury (odds ratio 0.50, 95% confidence interval 0.35–0.71) and reduced need of mechanical ventilation (odds ratio 0.62, 95% confidence interval 0.45–87). Incidence of acute kidney injury was similar between both groups (odds ratio 1.08, 95% confidence interval 0.73–1.59).Conclusions. The use of antiplatelet therapy before the diagnosis of severe sepsis or septic shock was not associated with decreased hospital mortality. Antiplatelet therapy was associated with a decreased incidence of acute lung injury/acute respiratory distress syndrome.
Risk Factors for Development of Acute Kidney Injury in Critically Ill Patients: A Systematic Review and Meta-Analysis of Observational Studies
Cartin‐Ceba, Rodrigo , Kashiouris, Markos , Plataki, Maria , Kor, Daryl J. , Casey, Edward T., Gajic, Ognjen

Critical Care Research and Practice | November 26, 2012 | Volume: 2012 | Issue: No issue available | Pages: 1-15

10.1155/2012/691013 | PMID 23227318 Get It

Background. Acute kidney injury (AKI) is a frequent complication of critically ill patients. The impact of different risk factors associated with this entity in the ICU setting is unknown.Objectives. The purpose of this research was to assess the risk factors associated with the development of AKI in critically ill patients by meta-analyses of observational studies.Data Extraction. Two reviewers independently and in duplicate used a standardized form to collect data from published reports. Authors were contacted for missing data. The Newcastle-Ottawa scale assessed study quality.Data Synthesis. Data from 31 diverse studies that enrolled 504,535 critically ill individuals from a wide variety of ICUs were included. Separate random-effects meta-analyses demonstrated a significantly increased risk of AKI with older age, diabetes, hypertension, higher baseline creatinine, heart failure, sepsis/systemic inflammatory response syndrome, use of nephrotoxic drugs, higher severity of disease scores, use of vasopressors/inotropes, high risk surgery, emergency surgery, use of intra-aortic balloon pump, and longer time in cardiopulmonary bypass pump.Conclusion. The best available evidence suggests an association of AKI with 13 different risk factors in subjects admitted to the ICU. Predictive models for identification of high risk individuals for developing AKI in all types of ICU are required.